chufangao/CTO huggingface dataset:
Clinical trial NCT03661138: A Study to Evaluate Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
Official title: A Phase 3 Randomized, Multicenter, Double-Blind Study to Evaluate the Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Subjects in Japan With Moderate to Severe Atopic Dermatitis
Acronym: Rising Up
Sponsor: AbbVie (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 272.0 (ACTUAL)
Number of arms: 4.0
Start date: 2018-10-27
Primary completion date: 2022-08-19
Completion date: 2022-08-19
Plan to share individual participant data: YES
IPD sharing description: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
IPD time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
IPD access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Clinical trial NCT04109092: A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102
Official title: INtravesical Phase 1/1b Study of STING Agonist E7766 in NMIBC Including Subjects Unresponsive to BCG Therapy, INPUT-102
Sponsor: Eisai Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: There was no enrolment of participants.Unscheduled Clinical Study Closure - Eisai Network Company Decision, November 12, 2020.
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-02-13
Primary completion date: 2022-09-29
Completion date: 2022-09-29
Plan to share individual participant data: YES
IPD sharing description: Eisai's data sharing commitment and further information on how to request data can be found on our website http://eisaiclinicaltrials.com/.
Clinical trial NCT04810689: Pilot Trial of XFBD, a TCM, in Persons With COVID-19
Official title: A Randomized, Double-Blind, Placebo-Control Pilot Trial of Xuanfei Baidu Granules (XFBD), a Traditional Chinese Medicine (TCM), in Persons With COVID-19
Sponsor: University of Southern California (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Futile Enrollment
Enrollment: 5.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-03-01
Primary completion date: 2022-06-20
Completion date: 2022-06-20
Clinical trial NCT03708354: Tocotrienols for Skeletal Muscle Health
Official title: Tocotrienols Supplementation for Postmenopausal Women With Low Muscle Strength
Acronym: VitE-muscle
Sponsor: Texas Tech University Health Sciences Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Difficulties in Recruiting
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-04-15
Primary completion date: 2022-12-31
Completion date: 2022-12-31
Plan to share individual participant data: NO
Clinical trial NCT03746587: Study of Arimoclomol in Patients Diagnosed With Gaucher Disease Type 1 or 3
Official title: Multicentre Double-blinded, Randomized Placebo-controlled Study of Arimoclomol in Patients Diagnosed With Gaucher Disease Type 1 or 3
Sponsor: ZevraDenmark (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: COVID-19 pandemic made it impossible to assess the trial objective
Enrollment: 39.0 (ACTUAL)
Number of arms: 4.0
Start date: 2018-06-06
Primary completion date: 2020-04-01
Completion date: 2021-10-15
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04406948: Study of Safety and Efficacy of MGCND00EP1 as an Add on Treatment in Children and Adolescents With Resistant Epilepsies
Official title: Randomized, Double Blind, Placebo Controlled, Parallel Design Phase II b Study of Safety and Efficacy of MGCND00EP1 as an Add on Treatment in Children and Adolescents With Resistant Epilepsies
Sponsor: MGC Pharmaceuticals d.o.o (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Failure to overcome bureaucratic obstacles within timeframe.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2024-05-30
Primary completion date: 2024-05-30
Completion date: 2024-05-30
Plan to share individual participant data: NO
Clinical trial NCT05229068: A Study of Safety, Reactogenicity and Immune Response of the Repeat Vaccination Against RSV When Given to Female Participants of 18-49 Years of Age During Their Subsequent Uncomplicated Pregnancy
Official title: A Phase IIIB, Open Label, Non-randomized, Controlled, Multi-country Study to Evaluate Safety, Reactogenicity and Immunogenicity of the Repeat Vaccination With 120 µg Dose of RSV Maternal Vaccine During Subsequent Pregnancy in Healthy Maternal Participants 18-49 Years of Age
Sponsor: GlaxoSmithKline (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Following a recommendation from the Independent Data Monitoring Committee of NCT04605159 (RSV MAT 009), GSK made the decision to stop enrolment and vaccination in this study.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-03-11
Primary completion date: 2023-11-06
Completion date: 2024-10-24
Plan to share individual participant data: YES
IPD sharing description: IPD for this study will be made available via the Clinical Study Data Request site.
IPD time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, a key secondary endpoints and safety data of the study.
IPD access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Clinical trial NCT03241641: Switching From TDF to TAF vs. Maintaining TDF in Chronic Hepatitis B With Resistance to Adefovir or Entecavir.
Official title: Switching From Tenofovir Disoproxil Fumarate(TDF) to Tenofovir AlaFenamide(TAF) vs. Maintaining TDF Monotherapy in Chronic Hepatitis B Patients With Genotypic Resistance to Adefovir or Entecavir
Sponsor: Asan Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 174.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-10-26
Primary completion date: 2021-03-25
Completion date: 2021-03-25
Plan to share individual participant data: NO
Clinical trial NCT03351608: Efficacy, Safety, and Pharmacokinetics of Sugammadex for Reversal of Neuromuscular Blockade (NMB) in Pediatric Participants (MK-8616-089)
Official title: A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants
Sponsor: Merck Sharp & Dohme LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 288.0 (ACTUAL)
Number of arms: 5.0
Start date: 2018-02-12
Primary completion date: 2020-01-28
Completion date: 2020-01-28
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Clinical trial NCT04512066: A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
Official title: A Phase II, Multi-Center, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 287.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-09-08
Primary completion date: 2022-06-21
Completion date: 2022-06-21
Baseline population: The efficacy analysis population (EAP) was used to determine baseline characteristics. The EAP included all randomized participants who received at least one dose of study medication and who had primary efficacy assessments at baseline and on at least one occasion post-baseline.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Clinical trial NCT04115748: Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy
Official title: A Phase 3, Randomized, Double-blind, Placebo and Adalimumab-controlled Study to Evaluate the Efficacy and Safety of Filgotinib in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy
Acronym: PENGUIN 1
Sponsor: Gilead Sciences (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Development program terminated
Enrollment: 67.0 (ACTUAL)
Number of arms: 6.0
Start date: 2019-12-03
Primary completion date: 2021-01-19
Completion date: 2021-05-11
Baseline population: Safety Analysis Set included all participants who received at least 1 dose of study drug.
Limitations and caveats: Due to early termination of the study and insufficient number of participants enrolled, all the hypothesis testing performed and the p values reported were nominal. Therefore, the results need to be interpreted with caution.
Plan to share individual participant data: NO
Clinical trial NCT04211831: URO-902 in Female Subjects With Overactive Bladder and Urge Urinary Incontinence
Official title: An Exploratory Phase 2a Study Evaluating the Efficacy and Safety of URO-902 in Subjects With Overactive Bladder and Urge Urinary Incontinence
Sponsor: Urovant Sciences GmbH (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 80.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-12-16
Primary completion date: 2021-11-18
Completion date: 2022-07-20
Baseline population: Intent- to-treat Exposed (ITT-E) population was defined as all participants who were randomized and treated.
Plan to share individual participant data: NO
Clinical trial NCT04785547: ALL SCTped 2012 FORUM Add-on Study Blina Post HSCT
Official title: A Phase II Study of Blincyto in Children With CD19+ Precursor B-lineage ALL and MRD-Positivity Before and/or Following First Allogeneic HSCT
Sponsor: St. Anna Kinderkrebsforschung (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Terminated by Amgen Limited
Enrollment: 3.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-12-17
Primary completion date: 2022-01-22
Completion date: 2022-01-22
Clinical trial NCT04493333: Vaginal Dehydroepiandrosterone (DHEA) in Postmenopausal Breast Cancer Survivors on Aromatase Inhibitors
Official title: Comparison of Vaginal Dehydroepiandrosterone (DHEA) to Control for Treatment of Vaginal Symptoms in Postmenopausal Breast Cancer Survivors on Aromatase Inhibitors: A Phase II Randomized Trial
Sponsor: University of Arkansas (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Low recruitment/enrollment
Enrollment: 8.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-06-07
Primary completion date: 2023-07-18
Completion date: 2023-07-18
Baseline population: Postmenopausal females between 18 and 70 with a history of breast cancer.
Limitations and caveats: Early termination due to low enrollment and lack of subject participation/noncompliance.
Clinical trial NCT03258723: Diabetes Prevention With Lifestyle Intervention and Metformin Escalation
Official title: Diabetes Prevention With Lifestyle Intervention and Metformin Escalation
Acronym: LIME
Sponsor: Yale University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: COVID-19 led to changes in study design and an early end to data collection.
Enrollment: 114.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-07-30
Primary completion date: 2021-12-01
Completion date: 2021-12-01
Plan to share individual participant data: NO
Clinical trial NCT03905343: Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBC
Official title: Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line Treatment in Patients With Visceral Metastatic Breast Cancer. A Multicenter, Randomized Phase III Trial.
Sponsor: Swiss Group for Clinical Cancer Research (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Feasibility (low patient accrual and financial reasons)
Enrollment: 25.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-06-25
Primary completion date: 2021-04-15
Completion date: 2021-04-15
Clinical trial NCT04143945: A Study Comparing the Injection Site Pain Experience After the Injection of Semaglutide B and Semaglutide D With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity
Official title: A Trial to Compare the Injection Site Pain Experience of 0.25 mg Semaglutide B and Semaglutide D Administered sc
Sponsor: Novo Nordisk A/S (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 104.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-10-28
Primary completion date: 2020-01-04
Completion date: 2020-01-04
Baseline population: The full analysis set included all participants who had received at least 1 injection of semaglutide (included any skin contact with trial product whether the injection was completed or not).
Plan to share individual participant data: YES
IPD sharing description: According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Clinical trial NCT05310071: A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease
Official title: A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants With Alzheimer's Disease
Acronym: ENVISION
Sponsor: Biogen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Sponsor's Decision
Enrollment: 1027.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-06-02
Primary completion date: 2024-08-12
Completion date: 2024-08-12
Plan to share individual participant data: YES
IPD sharing description: In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/
Clinical trial NCT04225676: Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia (ALL)
Official title: A Phase II, Open Label, Multi-center Trial to Determine the Efficacy and Safety of Tisagenlecleucel Re-infusion in Pediatric and Adolescent Young Adult (AYA) Patients With Acute Lymphoblastic Leukemia Experiencing Loss of B Cell Aplasia
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Terminated due to slow enrollment
Enrollment: 5.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-10-19
Primary completion date: 2021-10-19
Completion date: 2021-10-19
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data is currently available according to the process described on www.clinicalstudydatarequest.com.
Clinical trial NCT04729595: Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients.
Official title: A Phase 2/3, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study to Examine the Effects of Tempol (MBM-02) in Subjects With COVID-19 Infection
Sponsor: Adamis Pharmaceuticals Corporation (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: Study did not demonstrate statistical significance of its primary endpoint of clinical resolution of COVID-19 symptoms at day 14 versus placebo
Enrollment: 248.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-09-01
Primary completion date: 2022-09-21
Completion date: 2022-09-21
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04790903: A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)
Official title: A Phase Ib Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Patients With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Decision to discontinue the study based on broader development and strategic prioritisation. The Sponsor concludes there is no benefit-risk impact on the BO42203 study.
Enrollment: 50.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-07-02
Primary completion date: 2024-05-21
Completion date: 2024-05-21
Plan to share individual participant data: NO
IPD sharing description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Clinical trial NCT03860844: Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
Official title: Open-label, Single-arm Trial to Evaluate Antitumor Activity, Safety, and Pharmacokinetics of Isatuximab Used in Combination With Chemotherapy in Pediatric Patients From 28 Days to Less Than 18 Years of Age With Relapsed/Refractory B or T Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia in First or Second Relapse
Acronym: ISAKIDS
Sponsor: Sanofi (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Study was prematurely stopped due to sponsor decision (stage 2 efficacy criteria not met); not due to safety concerns.
Enrollment: 67.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-08-06
Primary completion date: 2022-09-12
Completion date: 2023-05-26
Baseline population: The All-treated (AT) population consisted of all participants who received at least 1 dose (even incomplete) of study treatment.
Limitations and caveats: The study was prematurely stopped due to sponsor decision (stage 2 efficacy criteria not met) and not due to safety concerns.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Clinical trial NCT04020341: A Study to Evaluate Efficacy and Safety of Gepotidacin in the Treatment of Uncomplicated Urinary Tract Infection (UTI)
Official title: A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)
Sponsor: GlaxoSmithKline (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1531.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-10-17
Primary completion date: 2022-11-30
Completion date: 2022-11-30
Baseline population: Participants randomly assigned to the study treatment were included in the ITT population.
Plan to share individual participant data: YES
IPD sharing description: IPD for this study will be made available via the Clinical Study Data Request site.
IPD time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
IPD access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Clinical trial NCT03843853: Pemetrexed and S-1 in Combination With Bevacizumab in Refractory Colorectal Cancer
Official title: A Single Arm, Open Label, Exploratory Study of Pemetrexed and S-1 in Combination With Bevacizumab in Patients Who Have Progressed After Standard Second Line Therapy
Sponsor: The First Affiliated Hospital with Nanjing Medical University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: cooperation terminated
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-05-01
Primary completion date: 2021-11-01
Completion date: 2022-05-01
Plan to share individual participant data: NO
Clinical trial NCT05627791: Effects of Vaginal Oxytocin Gel on Vaginal Cytologic Parameters in Postmenopausal Woman
Official title: Effects of Vaginal Oxytocin Gel on Vaginal Cytologic Parameters in Postmenopausal Woman: A Randomized Placebo-controlled Trial
Sponsor: Rajavithi Hospital (OTHER_GOV)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: Unable to recuit participant number in time.
Enrollment: 6.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-11-30
Primary completion date: 2023-07-31
Completion date: 2023-08-28
Plan to share individual participant data: NO